{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:05:40Z","timestamp":1784199940788,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2017-3451"],"award-info":[{"award-number":["2017-3451"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["SRF"],"award-info":[{"award-number":["SRF"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/53\/2018-PHA\/BMS\/OL"],"award-info":[{"award-number":["45\/53\/2018-PHA\/BMS\/OL"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jchromb.2019.121962","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T11:46:42Z","timestamp":1577706402000},"page":"121962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction"],"prefix":"10.1016","volume":"1138","author":[{"given":"Misari","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmy","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2019.121962_b0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1152\/ajprenal.00045.2010","article-title":"Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection","author":"Zoja","year":"2010","journal-title":"Am. J. Physiol.-Renal Physiol."},{"key":"10.1016\/j.jchromb.2019.121962_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7888\/juoeh.26.165","article-title":"Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats","volume":"26","author":"Nie","year":"2004","journal-title":"J. UOEH"},{"issue":"5","key":"10.1016\/j.jchromb.2019.121962_b0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1872-2059(07)60025-X","article-title":"Determination of pitavastatin from human plasma using high performance liquid chromatography with fluorescence detection","volume":"25","author":"Ashwini","year":"2007","journal-title":"Chin. J. Chromatogr."},{"key":"10.1016\/j.jchromb.2019.121962_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2007.07.022","article-title":"Determination of pitavastatin in human plasma via HPLC-ESI-MS\/MS and subsequent application to a clinical study in healthy Chinese volunteers","volume":"386","author":"Lv","year":"2007","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.jchromb.2019.121962_b0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jchromb.2008.04.036","article-title":"Solid-phase extraction and liquid chromatography\/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies","volume":"868","author":"Di","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2019.121962_b0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2008.02.017","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometric assay for pitavastatin and its lactone in human plasma and urine","author":"Tian","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 865"},{"key":"10.1016\/j.jchromb.2019.121962_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpba.2012.09.026","article-title":"Simple LC-MS\/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a phar","volume":"72","author":"Qi","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2019.121962_b0040","first-page":"348","article-title":"LC-MS\/MS assay for pitavastatin in human plasma and subsequent application to a clinical study in healthy Chinese volunteers","volume":"9","author":"Yin","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2019.121962_b0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0378-4347(99)00247-9","article-title":"Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection","volume":"731","author":"Stenhoff","year":"1999","journal-title":"J. Chromatogr. B. Biomed. Sci. Appl."},{"key":"10.1016\/j.jchromb.2019.121962_b0050","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1096-9888(199608)31:8<873::AID-JMS368>3.0.CO;2-J","article-title":"Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography\/electrospray tandem mass spectrometry following chemical derivatization","volume":"31","author":"Kondo","year":"1996","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2019.121962_b0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/2229-4708.84460","article-title":"Development and validation of the liquid chromatography-tandem mass spectrometry method for quantitative estimation of candesartan from human plasma","volume":"2","author":"Prajapati","year":"2011","journal-title":"Pharm. Methods."},{"key":"10.1016\/j.jchromb.2019.121962_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0378-4347(95)00405-X","article-title":"Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine","volume":"677","author":"Miyabayashi","year":"1996","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jchromb.2019.121962_b0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0378-4347(95)00146-8","article-title":"Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine","volume":"670","author":"Lee","year":"1995","journal-title":"J. Chromatogr. B. Biomed. Appl."},{"key":"10.1016\/j.jchromb.2019.121962_b0070","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/10826076.2011.615092","article-title":"Rapid determination of candesartan in human plasma by liquid chromatography tandem mass spectrometry and its application to a bioequivalence study","volume":"35","author":"Lou","year":"2012","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jchromb.2019.121962_b0075","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3109\/03639045.2012.725732","article-title":"Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers","volume":"39","author":"Jeon","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jchromb.2019.121962_b0080","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2010.10.013","article-title":"Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism","volume":"149","author":"Gao","year":"2011","journal-title":"J. Control. Release."},{"key":"10.1016\/j.jchromb.2019.121962_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/bmc.905","article-title":"Kwang-Hyeon Liu 1, 2 and Jae-Gook Shin1, Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography\u2013tandem mass spectrometry for pharmaceutical study","volume":"22","author":"Deng","year":"2008","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2019.121962_b0090","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00228-013-1554-0","article-title":"Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers","volume":"69","author":"Chen","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2019.121962_b0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpba.2016.09.006","article-title":"Simultaneous determination of telmisartan and pitavastatin in rat plasma by UPLC\u2013MS\/MS: Application to pharmacokinetic interaction study","volume":"131","author":"Chen","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2019.121962_b0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jchromb.2017.01.009","article-title":"A validated LC\u2013MS\/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies","volume":"1046","author":"Surendran","year":"2017","journal-title":"J. Chromatogr. B Anal. Technol. Biomed Life Sci."},{"key":"10.1016\/j.jchromb.2019.121962_b0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpha.2012.01.002","article-title":"Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS\/MS and its application to a human pharmacokinetic study","volume":"2","author":"Kumari Karra","year":"2012","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jchromb.2019.121962_b0110","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.4155\/bio.12.83","article-title":"LC\u2013MS\/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics","volume":"4","author":"Bharathi","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2019.121962_b0115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpha.2013.05.003","article-title":"Improved simultaneous quantitation of candesartan and hydrochlorthiazide in human plasma by UPLC-MS\/MS and its application in bioequivalence studies","volume":"4","author":"Singh","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jchromb.2019.121962_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4607","article-title":"A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: application to pharmacokinetic interaction study","author":"Patel","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2019.121962_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2016.10.011","article-title":"Critical review of statins: a bio-analytical perspective for therapeutic drug monitoring","volume":"86","author":"Patel","year":"2017","journal-title":"TrAC \u2013 Trends Anal. Chem."},{"key":"10.1016\/j.jchromb.2019.121962_b0130","series-title":"FDA Guidance for Industry: Bioanalytical Method Validation","author":"Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jchromb.2019.121962_b0135","unstructured":"Guidance for industry starting dose in initial clinical trials guidance for industry estimating the maximum safe, 2005."},{"key":"10.1016\/j.jchromb.2019.121962_b0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.jchromb.2019.121962_b0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1567-5688(11)70886-8","article-title":"Pitavastatin: an overview","volume":"12","author":"Saito","year":"2011","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.jchromb.2019.121962_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/clp.12.21","article-title":"Pitavastatin: a different pharmacological profile","volume":"7","author":"Catapano","year":"2012","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.jchromb.2019.121962_b0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003088-200241010-00002","article-title":"Clinical pharmacokinetics of candesartan","volume":"41","author":"Gleiter","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2019.121962_b0160","first-page":"12","article-title":"A review on candesartan: pharmacological and pharmaceutical profile","volume":"01","author":"Husain","year":"2011","journal-title":"J. Appl. Pharm. Sci."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219315533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219315533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T22:59:44Z","timestamp":1761605984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023219315533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":32,"alternative-id":["S1570023219315533"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2019.121962","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2019.121962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121962"}}